MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, the stockholders of Poseida will receive only $9.00 per share, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share upon achievement of specific milestones, totaling an equity value of approximately $1.5 billion on a fully diluted basis.
The transaction agreement unreasonably limits competing transactions for Poseida by imposing a significant penalty if Poseida accepts a competing bid. Poseida insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Poseida’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
